OpenAI Acquires Bio Startup Orchestra Bio to Boost Its Biotech Business
Original headline: OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI announced that it has acquired the biotech startup Orchestra Bio, integrating its team and technology. The acquisition is aimed at strengthening OpenAI’s AI model for life‑science research, Rosalind, and its accompanying Rosalind Workbench tool.
Combining AI with biotechnology is expected to markedly accelerate drug discovery and research efficiency.
Research angleHow does the introduction of OpenAI’s biotech AI platform affect researchers’ technology acceptance? — Technology Acceptance Model (TAM)
2 related reports
This story could become your next paper
HJITM works with researchers from study design through surveys, analysis and submission to international journals in generative AI and technology management. Bring us your research question.
This item is an AI-generated summary of reporting by TechCrunch. Please check the original article for accuracy. Copyright in the original article belongs to TechCrunch.